Jesper F Kallehauge
Overview
Explore the profile of Jesper F Kallehauge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochreuter K, Buti G, Ajdari A, Bridge C, Sharp G, Jespersen S, et al.
Phys Imaging Radiat Oncol
. 2025 Jan;
33:100688.
PMID: 39866246
Background And Purpose: Diffusion tensor imaging (DTI) has been proposed to guide the anisotropic expansion from gross tumor volume to clinical target volume (CTV), aiming to integrate known tumor spread...
2.
Danielsen J, Zachariae R, Schmidt H, Kallehauge J, Thomadsen J, Wefel J, et al.
Cancer
. 2024 Dec;
131(2):e35683.
PMID: 39663713
Background: Cancer-related cognitive impairment (CRCI) is a significant concern in patients with cancer but understanding its prevalence and risk factors in patients with malignant melanoma (MMPs) remains limited. This study...
3.
Hochreuter K, Ren J, Nijkamp J, Korreman S, Lukacova S, Kallehauge J, et al.
Phys Imaging Radiat Oncol
. 2024 Sep;
31:100620.
PMID: 39220114
Background And Purpose: Deep-learning (DL) models for segmentation of the gross tumor volume (GTV) in radiotherapy are generally based on clinical delineations which suffer from inter-observer variability. The aim of...
4.
Amidi A, Haldbo-Classen L, Kallehauge J, Wu L, Zachariae R, Lassen-Ramshad Y, et al.
Acta Oncol
. 2023 Sep;
62(11):1520-1525.
PMID: 37688522
No abstract available.
5.
Ronde H, Kronborg C, Hoyer M, Hansen J, Bak M, Agergaard S, et al.
Acta Oncol
. 2023 Sep;
62(10):1222-1229.
PMID: 37683054
Background: Patients with stage II seminoma have traditionally been treated with photons to the retroperitoneal and iliac space, which leads to a substantial dose bath to abdominal and pelvic organs...
6.
Bargallo H, Stick L, Korreman S, Kronborg C, Nielsen M, Borgen A, et al.
Acta Oncol
. 2023 Aug;
62(11):1546-1550.
PMID: 37584197
No abstract available.
7.
Byskov C, Hansen C, Dahlrot R, Haldbo-Classen L, Haslund C, Kjaer-Kristoffersen F, et al.
Phys Imaging Radiat Oncol
. 2021 Dec;
20:98-104.
PMID: 34888422
Background And Purpose: Patients with lower-grade gliomas are long-term survivors after radiotherapy and may benefit from the reduced dose to normal tissue achievable with proton therapy. Here, we aimed to...
8.
Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer
van Houdt P, Kallehauge J, Tanderup K, Nout R, Zaletelj M, Tadic T, et al.
Radiother Oncol
. 2020 Sep;
153:114-121.
PMID: 32931890
Background And Purpose: A wide variation of MRI systems is a challenge in multicenter imaging biomarker studies as it adds variation in quantitative MRI values. The aim of this study...
9.
Franklin J, Irving B, Papiez B, Kallehauge J, Wang L, Goldin R, et al.
Eur J Radiol
. 2020 Mar;
126:108934.
PMID: 32217426
Purpose: To use a novel segmentation methodology based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to define tumour subregions of liver metastases from colorectal cancer (CRC), to compare these with...
10.
Trip A, Jensen M, Kallehauge J, Lukacova S
Acta Oncol
. 2019 Jul;
58(10):1532-1535.
PMID: 31303079
No abstract available.